Patents Assigned to Hydra Biosciences, LLC
-
Patent number: 11958854Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.Type: GrantFiled: November 10, 2021Date of Patent: April 16, 2024Assignee: Hydra Biosciences, LLCInventors: Bertrand L. Chenard, Randall J. Gallaschun
-
Publication number: 20230040259Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.Type: ApplicationFiled: November 10, 2021Publication date: February 9, 2023Applicant: Hydra Biosciences, LLCInventors: Bertrand L. Chenard, Randall J. Gallaschun
-
Patent number: 11485740Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: February 13, 2019Date of Patent: November 1, 2022Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
-
Publication number: 20220177479Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.Type: ApplicationFiled: November 10, 2021Publication date: June 9, 2022Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventor: Kai Gerlach
-
Publication number: 20220056032Abstract: The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.Type: ApplicationFiled: December 10, 2019Publication date: February 24, 2022Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventor: Kai Gerlach
-
Patent number: 11208409Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.Type: GrantFiled: April 29, 2019Date of Patent: December 28, 2021Assignee: Hydra Biosciences, LLCInventors: Bertrand L. Chenard, Randall J. Gallaschun
-
Patent number: 11198696Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.Type: GrantFiled: December 11, 2019Date of Patent: December 14, 2021Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventor: Kai Gerlach
-
Publication number: 20210163449Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: December 8, 2020Publication date: June 3, 2021Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Patent number: 10800757Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: October 25, 2018Date of Patent: October 13, 2020Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Patent number: RE49699Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu